Ying | Luxfen eye drops 0.2% fl-cap 5ml
Special Price
$22.31
Regular Price
$30.00
In stock
SKU
BID474044
Latin name
LUXFEN
LUXFEN
Latin name
LUXFEN
Release form
Eye drops 0.2%.
Packing
5 ml dropper bottle.
Pharmacological action
Anti-glaucoma drug. Brimonidine is a selective 2-adrenergic receptor agonist.
On installation 0. 2% brimonidine solution, a decrease in intraocular pressure is 10-12 mm RT. Art., the maximum effect is observed after 2 hours, the duration of action is 12 hours.
Brimonidine has a double mechanism of action: it reduces intraocular pressure by reducing the synthesis of intraocular fluid and enhancing uveoscleral outflow.
Pharmacokinetics
Absorption and distribution of
Upon instillation of eye drops Cmax of the drug in blood plasma is achieved after 0.5-2.5 hours. Binding to blood proteins when applied topically is 29%. Systemic absorption of brimonidine is slow. After using the drug 2 times / day for 10 days, the concentration of brimonidine in the plasma remains low (on average 0.06 ng / ml).
Metabolism and distribution
The drug is metabolized primarily in the liver. Brimonidine and its metabolites are excreted by the kidneys. T1 / 2 is about 2 hours.
Indications
Open-angle glaucoma, ophthalmic hypertension (in monotherapy and in combination with other drugs that reduce intraocular pressure).
Contraindications
Hypersensitivity to the components of the drug
simultaneous therapy with monoamine oxidase inhibitors (MAOs) and tricyclic antidepressants
children under 2 years of age
period of breastfeeding.
Caution: when using the drug in patients with a severe, unstable and uncontrolled form of cardiovascular disease, with cerebral or coronary insufficiency, depression, orthostatic hypotension, Raynaud's disease, thromboangiitis obliterans in case of impaired liver or kidney function, children from 2 to 18 years.
Pregnancy and lactation
Safety and efficacy studies of brimonidine in pregnant and lactating women have not been conducted. In animal studies, topical application of brimonidine did not lead to impaired intrauterine development.
There is no accurate data on the penetration of brimonidine into breast milk when applied topically.
However, the risk cannot be completely ruled out.
The use of brimonidine during pregnancy is allowed only in cases where the expected benefits to the mother outweigh the potential risk to the fetus or child.
When prescribed during lactation, breastfeeding is recommended to be discontinued during treatment.
Composition
1 ml eye drops contains:
Active ingredient:
brimonidine tartrate - 2.0 mg.
Excipients:
benzalkonium chloride (in terms of 100% substance) - 0.052 mg,
polyvinyl alcohol - 14.0 mg,
sodium chloride - 6.90 mg,
sodium citrate dihydrate - 4.70 mg,
citric acid monohydrate - 0.48 mg,
hydrochloric acid - up to pH 6.45,
sodium hydroxide - up to pH 6.45,
water - up to 1 ml.
Dosage and Administration
Topically.
Instill 1 drop of the drug 2 times a day.
Duration of treatment is determined by the physician.
Side effects
The frequency of side effects is classified as follows:
very often (> 1/10)
often (>> 1/100 to <1/10)
sometimes (>> 1/1000 to <1/100)
rare (> 1/10 000 to <1/1000)
very rare (<1/10 000)
frequency unknown (side effects with unknown frequency).
From the side of the organs of vision: very often - allergic conjunctivitis, conjunctival hyperemia, itching of the eyelids and mucous membranes of the eyes often - burning sensation, follicular conjunctiva of the eyes and follicular conjunctivitis, local allergic reactions of the mucous membrane of the eyes (including keratoconjunctivitis,) , violation of the clarity of visual perception, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, retention lacrimation, mucous discharge from the eyes, dryness and irritation of the eye mucosa, pain, eyelid edema, redness of the eyelids, sensation of a foreign body in the eyes, keratitis, eyelid damage, photosensitivity, superficial spotty keratopathy, lacrimation, loss of visual field, functional lesion of the vitreous humor, vitreous hemorrhage, floating opacities in the vitreous and decrease in Trot view infrequently - corneal erosion and barley.
From the central nervous system: often - headache, drowsiness, insomnia, dizziness.
From the cardiovascular system: often - increase in blood pressure infrequently - decrease in blood pressure.
On the part of the respiratory system: often - bronchitis, cough, shortness of breath infrequently - dryness of the nasal mucosa apnea.
From the gastrointestinal tract: often - gastrointestinal disorders - dyspepsia, dry oral mucosa.
From the skin and subcutaneous fat: often - rashes.
Infectious and parasitic diseases: often - flu-like syndrome, infectious disease (chills and respiratory infection), rhinitis, sinusitis, including infectious.
Laboratory indicators: often - hypercholesterolemia.
Others: often - general allergic reactions, asthenia, fatigue infrequently - a change in taste.
Children noted: apnea, bradycardia, lowering blood pressure, hypothermia, muscle hypotension.
Additionally obtained data on the following effects:
From the side of the organs of vision: the frequency is unknown - iritis, keratoconjunctivitis, miosis.
From the central nervous system: depression.
From the cardiovascular system: bradycardia, tachycardia.
From the gastrointestinal tract: nausea.
From the skin and subcutaneous fat: local skin reactions (erythema, itching, facial swelling, rash and vasodilation of the vessels of the skin of the eyelids).
Drug Interaction
Brimonidine at a concentration of 2 mg / ml can enhance the action of substances that affect the central nervous system (alcohol, barbiturates, opioids, sedatives and anesthetics). Caution should be exercised when taking drugs that can affect the absorption and metabolism of adrenaline, norepinephrine and other so-called biogenic amines (chlorpromazine, methylphenidate, reserpine).
A slight decrease in blood pressure has been observed in some patients after the administration of brimonidine at a concentration of 2 mg / ml. Caution should be exercised when used concomitantly with antihypertensive drugs and / or preparations of the group of cardiac glycosides (digitalis).
For the first time systemic administration of agonists or antagonists of adrenergic receptors (eg, isoprenaline or prazosin) for the first time, as well as changing the dose of these simultaneously administered systemic drugs (regardless of the method of their administration), interactions with alpha-adrenoceptor agonists or agonists may occur. effects.
Overdose
Overdose is extremely rare.
Symptoms: accidental administration of the drug inside are possible - central nervous system depression, drowsiness, depression and loss of consciousness, decrease in blood pressure, bradycardia, decrease in body temperature, cyanosis of the skin, apnea.
Treatment: Supportive symptomatic therapy, control of airway patency.
Storage conditions
Store at a temperature not exceeding 25 РC.
Keep out of the reach of children.
Expiration
2 years. Expiration after opening the bottle is 4 weeks.
dosage form
dosage form
eye drops
LUXFEN
Release form
Eye drops 0.2%.
Packing
5 ml dropper bottle.
Pharmacological action
Anti-glaucoma drug. Brimonidine is a selective 2-adrenergic receptor agonist.
On installation 0. 2% brimonidine solution, a decrease in intraocular pressure is 10-12 mm RT. Art., the maximum effect is observed after 2 hours, the duration of action is 12 hours.
Brimonidine has a double mechanism of action: it reduces intraocular pressure by reducing the synthesis of intraocular fluid and enhancing uveoscleral outflow.
Pharmacokinetics
Absorption and distribution of
Upon instillation of eye drops Cmax of the drug in blood plasma is achieved after 0.5-2.5 hours. Binding to blood proteins when applied topically is 29%. Systemic absorption of brimonidine is slow. After using the drug 2 times / day for 10 days, the concentration of brimonidine in the plasma remains low (on average 0.06 ng / ml).
Metabolism and distribution
The drug is metabolized primarily in the liver. Brimonidine and its metabolites are excreted by the kidneys. T1 / 2 is about 2 hours.
Indications
Open-angle glaucoma, ophthalmic hypertension (in monotherapy and in combination with other drugs that reduce intraocular pressure).
Contraindications
Hypersensitivity to the components of the drug
simultaneous therapy with monoamine oxidase inhibitors (MAOs) and tricyclic antidepressants
children under 2 years of age
period of breastfeeding.
Caution: when using the drug in patients with a severe, unstable and uncontrolled form of cardiovascular disease, with cerebral or coronary insufficiency, depression, orthostatic hypotension, Raynaud's disease, thromboangiitis obliterans in case of impaired liver or kidney function, children from 2 to 18 years.
Pregnancy and lactation
Safety and efficacy studies of brimonidine in pregnant and lactating women have not been conducted. In animal studies, topical application of brimonidine did not lead to impaired intrauterine development.
There is no accurate data on the penetration of brimonidine into breast milk when applied topically.
However, the risk cannot be completely ruled out.
The use of brimonidine during pregnancy is allowed only in cases where the expected benefits to the mother outweigh the potential risk to the fetus or child.
When prescribed during lactation, breastfeeding is recommended to be discontinued during treatment.
Composition
1 ml eye drops contains:
Active ingredient:
brimonidine tartrate - 2.0 mg.
Excipients:
benzalkonium chloride (in terms of 100% substance) - 0.052 mg,
polyvinyl alcohol - 14.0 mg,
sodium chloride - 6.90 mg,
sodium citrate dihydrate - 4.70 mg,
citric acid monohydrate - 0.48 mg,
hydrochloric acid - up to pH 6.45,
sodium hydroxide - up to pH 6.45,
water - up to 1 ml.
Dosage and Administration
Topically.
Instill 1 drop of the drug 2 times a day.
Duration of treatment is determined by the physician.
Side effects
The frequency of side effects is classified as follows:
very often (> 1/10)
often (>> 1/100 to <1/10)
sometimes (>> 1/1000 to <1/100)
rare (> 1/10 000 to <1/1000)
very rare (<1/10 000)
frequency unknown (side effects with unknown frequency).
From the side of the organs of vision: very often - allergic conjunctivitis, conjunctival hyperemia, itching of the eyelids and mucous membranes of the eyes often - burning sensation, follicular conjunctiva of the eyes and follicular conjunctivitis, local allergic reactions of the mucous membrane of the eyes (including keratoconjunctivitis,) , violation of the clarity of visual perception, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, retention lacrimation, mucous discharge from the eyes, dryness and irritation of the eye mucosa, pain, eyelid edema, redness of the eyelids, sensation of a foreign body in the eyes, keratitis, eyelid damage, photosensitivity, superficial spotty keratopathy, lacrimation, loss of visual field, functional lesion of the vitreous humor, vitreous hemorrhage, floating opacities in the vitreous and decrease in Trot view infrequently - corneal erosion and barley.
From the central nervous system: often - headache, drowsiness, insomnia, dizziness.
From the cardiovascular system: often - increase in blood pressure infrequently - decrease in blood pressure.
On the part of the respiratory system: often - bronchitis, cough, shortness of breath infrequently - dryness of the nasal mucosa apnea.
From the gastrointestinal tract: often - gastrointestinal disorders - dyspepsia, dry oral mucosa.
From the skin and subcutaneous fat: often - rashes.
Infectious and parasitic diseases: often - flu-like syndrome, infectious disease (chills and respiratory infection), rhinitis, sinusitis, including infectious.
Laboratory indicators: often - hypercholesterolemia.
Others: often - general allergic reactions, asthenia, fatigue infrequently - a change in taste.
Children noted: apnea, bradycardia, lowering blood pressure, hypothermia, muscle hypotension.
Additionally obtained data on the following effects:
From the side of the organs of vision: the frequency is unknown - iritis, keratoconjunctivitis, miosis.
From the central nervous system: depression.
From the cardiovascular system: bradycardia, tachycardia.
From the gastrointestinal tract: nausea.
From the skin and subcutaneous fat: local skin reactions (erythema, itching, facial swelling, rash and vasodilation of the vessels of the skin of the eyelids).
Drug Interaction
Brimonidine at a concentration of 2 mg / ml can enhance the action of substances that affect the central nervous system (alcohol, barbiturates, opioids, sedatives and anesthetics). Caution should be exercised when taking drugs that can affect the absorption and metabolism of adrenaline, norepinephrine and other so-called biogenic amines (chlorpromazine, methylphenidate, reserpine).
A slight decrease in blood pressure has been observed in some patients after the administration of brimonidine at a concentration of 2 mg / ml. Caution should be exercised when used concomitantly with antihypertensive drugs and / or preparations of the group of cardiac glycosides (digitalis).
For the first time systemic administration of agonists or antagonists of adrenergic receptors (eg, isoprenaline or prazosin) for the first time, as well as changing the dose of these simultaneously administered systemic drugs (regardless of the method of their administration), interactions with alpha-adrenoceptor agonists or agonists may occur. effects.
Overdose
Overdose is extremely rare.
Symptoms: accidental administration of the drug inside are possible - central nervous system depression, drowsiness, depression and loss of consciousness, decrease in blood pressure, bradycardia, decrease in body temperature, cyanosis of the skin, apnea.
Treatment: Supportive symptomatic therapy, control of airway patency.
Storage conditions
Store at a temperature not exceeding 25 РC.
Keep out of the reach of children.
Expiration
2 years. Expiration after opening the bottle is 4 weeks.
dosage form
dosage form
eye drops
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review